Found: 6
Select item for more details and to access through your institution.
Improved Glycemic Control Following Transition to Tubeless Insulin Pump Therapy in Adults With Type 1 Diabetes.
- Published in:
- Clinical Diabetes, 2021, v. 39, n. 1, p. 72, doi. 10.2337/cd20-0022
- By:
- Publication type:
- Article
Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy.
- Published in:
- Diabetes Care, 2023, v. 46, n. 4, p. 742, doi. 10.2337/dc22-1915
- By:
- Publication type:
- Article
1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1296-P
- By:
- Publication type:
- Article
978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-978-P
- By:
- Publication type:
- Article
215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-215-OR
- By:
- Publication type:
- Article
1061-P: Effect of the Omnipod<sup>®</sup> Insulin Management System on Glycemic Control in Adults with Type 1 Diabetes Previously Treated with MDI or CSII.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1061-P
- By:
- Publication type:
- Article